Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Elliquis

Bristol-Myers Squibb (BMS) building

Positive data for BMS’ clazakizumab in arthritis

Phase II results indicate drug is as effective as AbbVie’s Humira

Bristol-Myers Squibb (BMS) building

BMS bounces back to form in Q3

New launches in cancer, diabetes and RA help recovery from patent expiries

- PMLiVE

Pfizer calls for mHealth to be prioritised

Wants more action to support mobile health in developing countries' ageing populations

- PMLiVE

Xeljanz effective in psoriasis says Pfizer

Data backs extension of drug’s indications

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Adobe CEO joins Pfizer board

Shantanu Narayen joins corporate governance and science and technology committees

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

Bristol-Myers Squibb (BMS) building

BMS says it defends Sprycel patent in India

Blocks attempts to issue compulsory license for leukaemia drug

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

Bristol-Myers Squibb (BMS) building

BMS drops antidepressant in phase IIb

Liafensine no better than Lilly’s Cymbalta

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links